“Impact of Amlitelimab (An Anti-OX40 Ligand Antibody) on Maintenance of Itch Response in Atopic Dermatitis: Results From the 52-Week STREAM-AD Phase 2b Study”. SKIN The Journal of Cutaneous Medicine 9, no. 6 (November 10, 2025): s604. Accessed January 14, 2026. https://skin.dermsquared.com/skin/article/view/3883.